Obagi Medical Products, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY12 | FY11 | FY10 | FY09 | |
|---|---|---|---|---|
| Revenue | $30.8M | $26.5M | $112.8M | $104.1M |
| Operating income | $27.4M | $16.0M | $15.8M | $18.4M |
| Net income | $16.6M | $10.0M | $9.5M | $11.3M |
| Total assets | $82.1M | $77.7M | $62.7M | — |
| Total liabilities | $20.2M | $16.8M | $14.5M | — |
| Equity | $61.9M | $60.9M | $48.2M | $72.0M |
| EPS (diluted) | $0.16 | $-0.13 | $0.44 | $0.51 |
| Shares out. | 18.7M | 18.7M | 18.5M | 22.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2012- Operating margin
- 89.2%
- Net margin
- 54.1%
- Return on equity
- 26.9%
- Return on assets
- 20.3%
- Return on capital (ROCE)
- 43.1%
- Liabilities / assets
- 24.7%
- Debt / equity
- 0.33×
- Book value / share
- $3.31
- Revenue growth (YoY)
- 16.0%
- Net income growth (YoY)
- 66.0%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2012- Altman Z″ (distress)
- 11.39safe
- Accruals / assets
- −4.6%clean
- Beneish M-Score
- -2.79normal
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 7 good- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Unregistered equity sale · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsApr 26, 2013
- Entered a material agreement · Other material eventApr 3, 2013
- Entered a material agreement · Other material eventMar 20, 2013
- Results of operationsMar 14, 2013
- Other material eventDec 10, 2012
- Results of operationsNov 1, 2012
- Entered a material agreementOct 29, 2012
- Director / officer changeAug 16, 2012
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.